ARTELO BIOSCIENCES, INC. Derivative Liability, Current
ARTELO BIOSCIENCES, INC. (ARTL) had Derivative Liability, Current of $582.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-05-14
- 2026-03-31: Derivative Liability, Current $582.00K.
- 2025-12-31: Derivative Liability, Current $0.00.
- 2020-08-31: Derivative Liability, Current $0.00.
- 2019-08-31: Derivative Liability, Current $29.50M; Derivative Liability, Current as first filed $29.50K.
| Period end | Derivative Liability, Current | Derivative Liability, Current as first filed |
|---|---|---|
| 2026-03-31 | $582.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-05-14 | |
| 2020-08-31 | $0.00 10-K · filed 2021-11-29 | |
| 2019-08-31 | $29.50M 10-K · filed 2021-11-29 | $29.50K 10-K · filed 2019-11-25 |
| 2019-05-31 | $100.18K 10-Q · filed 2019-07-15 | |
| 2019-02-28 | $584.92K 10-Q · filed 2019-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |